We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
European drug price controls are threatening to provoke
a trade dispute with the U.S., the chief executive of the world's biggest pharmaceutical
company says.
In a move that could boost the market for HIV drugs, the Centers for Disease
Control and Prevention (CDC) has issued revised guidelines recommending that
physicians provide antiretroviral drugs to patients exposed to HIV from rapes,
accidents, injection-drug use or unsafe sex.
Drugmakers Pfizer and Schering-Plough made their presence
felt in the biotech industry recently, as both firms announced plans to acquire
biopharmaceutical firms.
Amid the growing uncertainty about the safety of Cox-2 inhibitors, Pfizer has
agreed to delay the European launch of Onsenal, a Cox-2 drug approved in the
EU for the treatment of intestinal polyps.
Martek Biosciences has received $81.4 million in net proceeds from its recent
stock offering, which it plans to use for capital expenditures, working capital
and general corporate purposes.
Eli Lilly has reported a surprise loss of $2.4 million in the fourth quarter,
caused not by operational difficulties but by a big tax bite on billions of
dollars it's bringing home from overseas and by a $36 million settlement-in-the-making
with the Justice Department over improper product marketing.